SCHEMBL1305813

SCHEMBL1305813

O=C(CCCC/C=C(\COc1cccc2ccccc12)C(=O)NCCC1C=CCCC1)NO

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ADAMTS4 O75173 1/20 0.41
▸ ADAMTS5 Q9UNA0 1/20 0.41
▸ PREP P48147 2/20 0.39
▸ ALDH1A1 P00352 4/20 0.38
▸ KDM4E B2RXH2 3/20 0.36
▸ HPGD P15428 3/20 0.36
▸ TDP1 Q9NUW8 1/20 0.36
▸ OGG1 O15527 1/20 0.36
▸ MAPT P10636 1/20 0.36
▸ HDAC1 Q13547 5/20 0.35
▸ HDAC6 Q9UBN7 5/20 0.35
▸ HDAC3 O15379 3/20 0.35
▸ HDAC2 Q92769 3/20 0.35
▸ HDAC4 P56524 2/20 0.35
▸ HDAC7 Q8WUI4 2/20 0.35
▸ HDAC10 Q969S8 2/20 0.35
▸ HDAC11 Q96DB2 2/20 0.35
▸ HDAC8 Q9BY41 2/20 0.35
▸ HDAC9 Q9UKV0 2/20 0.35
▸ HDAC5 Q9UQL6 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1306580 0.86 P2RX3 (0.47) ADAMTS4ADAMTS5PREPALDH1A1KDM4E
SCHEMBL21410409 0.83 PREP (0.41) ADAMTS4ADAMTS5PREPALDH1A1HDAC1
SCHEMBL1305810 0.83 ALDH1A1 (0.37) ADAMTS4ADAMTS5PREPALDH1A1KDM4E
SCHEMBL1305816 0.83 ALDH1A1 (0.37) ADAMTS4ADAMTS5PREPALDH1A1KDM4E
SCHEMBL29488485 0.81 HPGD (0.45) ALDH1A1KDM4EHPGDTDP1OGG1
SCHEMBL1305817 0.81 HPGD (0.45) ALDH1A1KDM4EHPGDTDP1OGG1
SCHEMBL1305811 0.81 HPGD (0.45) ALDH1A1KDM4EHPGDTDP1OGG1
SCHEMBL5017280 0.80 HRH3 (0.45) ADAMTS4ADAMTS5PREPALDH1A1KDM4E
SCHEMBL1305819 0.80 TDP1 (0.50) ALDH1A1KDM4EHPGDTDP1MAPT
SCHEMBL28392351 0.80 TDP1 (0.50) ALDH1A1KDM4EHPGDTDP1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US claimed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO claimed
EP-4026544-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY Crystalgenomics, Inc. (KR) 2022-07-13 — — EP claimed
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR CRYSTALGENOMICS, INC. (KR) 2021-11-11 — — US claimed
EP-3875081-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR Crystalgenomics, Inc. (KR) 2021-09-08 — — EP claimed
WO-2021045392-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY 크리스탈지노믹스(주) 2021-03-11 — — WO claimed
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME CRYSTALGENOMICS, INC. (KR) 2020-09-10 — — US claimed
EP-3640239-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME Crystalgenomics, Inc. (KR) 2020-04-22 — — EP claimed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP claimed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US claimed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US claimed
CN-101573327-A Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RES INST CHEM TECH (KR) 2009-11-04 — — CN claimed
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same CRYSTALGENOMICS, INC. (KR) 2023-05-23 — — US disclosed
EP-4155292-A1 METHOD FOR PRODUCING PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE Crystalgenomics, Inc. (KR) 2023-03-29 — — EP disclosed
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY CRYSTALGENOMICS, INC. (KR) 2022-09-15 — — US disclosed
WO-2022177054-A1 PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION 크리스탈지노믹스(주) 2022-08-25 — — WO disclosed
EP-2913322-A2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same Korea Research Institute Of Chemical Technology (KR) 2015-09-02 — — EP disclosed
US-8053435-B2 Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2011-11-08 — — US disclosed
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) 2010-03-18 — — US disclosed
CN-101573327-A Naphthalenyloxypropenyl derivatives having inhibitory activity against histone deacetylase and pharmaceutical composition comprising the same KOREA RES INST CHEM TECH (KR) 2009-11-04 — — CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220287993-A1 PHARMACEUTICAL COMPOSITION COMPRISING HDAC INHIBITOR AND ANTI-PD1 ANTIBODY OR ANTI PD-L1 ANTIBODY PDCD1, HDAC1, HDAC5 ADAMTS4 1078/4885ADAMTS5 917/4885PREP 1762/4885
US-20210346321-A1 PHARMACEUTICAL COMPOSITION CONTAINING ALKYL CARBAMOYL NAPHTHALENYLOXY OCTENOYL HYDROXYAMIDE PHOSPHATE, TARTRATE OR COMBINATION THEREOF, AND PREPARATION METHOD THEREFOR AGPAT5, NOTUM, HADH ADAMTS4 3918/4885ADAMTS5 3122/4885PREP 1863/4885
US-11655207-B2 Pharmaceutically acceptable salt of alkylcarbamoyl naphthalenyloxy octenoylhydroxy amide or of derivative thereof and method for preparing same DOHH, CYP51A1, ASAH2 ADAMTS4 2978/4885ADAMTS5 2917/4885PREP 848/4885
US-20100069630-A1 NAPHTHALENYLOXYPROPENYL DERIVATIVES HAVING INHIBITORY ACTIVITY AGAINST HISTONE DEACETYLASE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME HDAC1, HDAC3, HDAC11 ADAMTS4 2558/4885ADAMTS5 2842/4885PREP 1557/4885
US-20200283371-A1 PHARMACEUTICALLY ACCEPTABLE SALT OF ALKYLCARBAMOYL NAPHTHALENYLOXY OCTENOYLHYDROXYAMIDE OR OF DERIVATIVE THEREOF AND METHOD FOR PREPARING SAME DOHH, CYP51A1, CYP46A1 ADAMTS4 2679/4885ADAMTS5 2573/4885PREP 824/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback